XOOX, the world’s first pet networking service (PNS), creates buzz with its launch

XOOX LAB, INC

XOOX leads the pet networking services arena with its innovative features, including short-form content challenges, dedicated music for pets, and revolutionary health management.

– Popular for its short-form content challenges, pet music, illness diagnosis kit app, etc.

– Providing a newly conceptualized service with ID registration using pets’ eyes

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) — XOOX, a pet networking service (PNS) application featuring short-form content challenges, launched this month, winning over global pet owners. XOOX commenced its service with an advertisement in New York’s Times Square, underscoring its exclusive focus on our four-legged companions.

XOOX operates uniquely under pet accounts through Pet ID registration devised by XOOX’s global research and AI teams, including veterinary experts worldwide, utilizing innovative biometric identification techniques such as eyelid patterns and eye wrinkles. XOOX’s research team stated, “Through Pet ID, pets are recognized as account users on XOOX, allowing them to engage in various activities such as pet registration, insurance, health management, and making friends,” adding, “To enhance the accuracy of biometric recognition, we adopted a method that is a step up from nose prints and iris scans.”

In XOOX, pets become influencers through their IDs, boosting visibility by sharing their daily lives, engaging with followers, and participating in short-form content challenges. They earn points for various activities, usable in connected apps, for creating avatars, and for product purchases. Pet owners, known as Petlers, manage their pets’ IDs and support them in their activities. Striving to foster a positive shift in attitudes toward pets, XOOX welcomes individuals who currently do not own pets to also join. However, posting content is not a feature available to them at this time. Peter Kim, Technical Advisor at XOOX, said, “XOOX aims to create a positive space where modern individuals can escape from complicated reality and connect with their pets.” Kim added, “XOOX will allow pets to create more memories with their Petlers by utilizing a storyscaping approach and unique and informative services.”

The world of XOOX is full of exclusive content for pets. Its most popular music app (XOOX M) lets Petlers to select music that suits the pet’s preferences. The app, created through content development by XOOX’s music content affiliate Jo studios (CEO: Woojin Cho), is designed for pets waiting for their owners and currently hosts over 3,000 songs. Petlers can also create and upload their own music, earning points for popularity, which can be spent by their pets. XOOX M ensures a pet-friendly listening experience at a comfortable decibel level.

Additionally, a product developed with Push Pull System (CEO: Sungmyon Song) is in the works. By analyzing and utilizing deep learning techniques, it will determine whether pets truly enjoy music and do not perceive it as noise. The product will seamlessly sync with pet cameras and speakers, offering personalized music recommendations for your pets.

As a pet owner, it is worth paying attention to the app’s current launch promotion. In celebration of the launch, XOOX is giving away 10,000 free urine test kits to account holders worldwide. These test kits provide a simple way to detect illnesses through animal urine, making them ideal for pets in areas with limited access to veterinary care, helping to maintain the well-being of your beloved pets.

Furthermore, based on the launch of the pet urine diagnostic kit app with Medi Cloud, a global genetic analysis company based on NGS technology, XOOX will also launch applications that link pet DNA and MBTI.

Upon registration, 1 cent is automatically donated to the XOOX Foundation. These contributions will be directed towards campaigns across the globe aiming to positively influence pet-related legislation. With XOOX empowering pets to play a central role in our world, there is a strong belief that it will significantly contribute to creating a more supportive and pet-friendly environment.

Contact:

XOOX LAB, INC

www.xoox.pet

Kristen Kim

Tel.: +1 (213) 944-2679

Email: press@xoox.pet

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f092720-eaa2-478b-8bd4-99fa5c3fc51c

GlobeNewswire Distribution ID 8981332

The Coretec Group & University of Adelaide’s Research Work on CSpace Technology Selected for Presentation at SPIE Photonics West Conference

The presentation will detail the latest promising research discoveries in Coretec’s CSpace 3D display technology

ANN ARBOR, Mich., Nov. 21, 2023 (GLOBE NEWSWIRE) — The Coretec Group (OTCQB: CRTG), developers of silicon anode active materials for lithium-ion batteries, and cyclohexasilane (CHS) for EV, cleantech, and 3D display technology, today announced that its research in partnership with The University of Adelaide on its CSpace 3D volumetric display technology has been selected for presentation at the 2024 SPIE Photonics West Conference. Taking place in San Francisco, CA, on January 30, 2024 at 4:40 pm PST, the presentation details the most recent CSpace research developments. It will be given by Adelaide’s Dr. Yunle Wei.

The presentation is based on Coretec’s CSpace technology that utilizes two invisible infrared lasers to generate visible, 3D image pixels in glass within an imaging chamber. The research evaluated three types of alternative low-phonon-energy types of glass that possess high optical quality and the potential for mass manufacturing. Tellurite glass was found to be the most promising candidate, due to its high fluorescence efficiency for display and up-scalability of the imaging chamber size. The technology can be used in a wide array of applications including medical imaging, automotive and aerospace design, visualization in weather, defense monitoring, and many others.

“Our work with The Coretec Group has been highly beneficial and generated encouraging results,” said Dr. Wei, Post Doctoral Researcher at the University of Adelaide’s Institute for Photonics and Advanced Sensing (IPAS). “I look forward to connecting with and presenting our exciting results to fellow industry professionals.”

“We’re encouraged by the results from The University of Adelaide, and excited to share them with leaders in the photonics industry,” said Matt Kappers, CEO of The Coretec Group. “While our Company’s efforts continue to focus on Endurion, we are eager to pursue new milestones in the development of our CSpace technology, and aim to ultimately realize the shareholder value of this highly specialized product.”

About The Coretec Group

The Coretec Group, Inc. is an Ann Arbor, Michigan-based developer of engineered silicon and is using its expertise to develop silicon anodes for lithium-ion batteries that will charge faster and last longer. This program is called Endurion. Silicon has the theoretical ability to hold up to 10x the amount of lithium-ions as compared to traditional graphite. Through its proprietary nanoparticle approach, Endurion is loading silicon into the battery anode. A modest increase in silicon will be a game changer that will revolutionize the EV market as well as other energy storage applications.

Additionally, the Company is using its engineered silicon to develop a portfolio of other energy-focused products, including solid-state lighting (LEDs), semiconductors, and printable electronics. Coretec continues to develop CSpace, its 3D volumetric display technology with a wide array of applications including medical imaging, automotive, and others.

For more information, please visit thecoretecgroup.com.

Follow The Coretec Group on:

Twitter – @CoretecGroupInc
LinkedIn – www.linkedin.com/company/24789881
YouTube – www.youtube.com/channel/UC1IA9C6PoPd1G4M7B9QiZPQ/featured

Forward-Looking Statements

The statements in this press release that relate to The Coretec Group’s expectations with regard to the future impact on the Company’s results from operations are forward-looking statements and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the Company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity.

Corporate Contact:

The Coretec Group, Inc.
Lindsay McCarthy
info@thecoretecgroup.com
+1 (866) 916-0833

Media Contact:

Spencer Herrmann
FischTank PR
coretec@fischtankpr.com
+1 (518) 669-6818

GlobeNewswire Distribution ID 8982827

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Collaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization.

Boston, MA, Nov. 20, 2023 (GLOBE NEWSWIRE) — Genomic medicine, also known as precision medicine, offers transformative opportunities to reshape health care and public health from a ‘one size fits all’ approach to one utilizing an individual’s genetic profile, informing their personalized care pathway from prevention and diagnosis, to treatment of diseases and the development of novel and more effective drugs. To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling. This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology. The comprehensive partnership between iCGD, Mass General Brigham, and the Department of Health – Abu Dhabi will help advance life sciences and health care outcomes across the globe while leveraging the advanced genomics capabilities of the Emirate.

With an emphasis on screening, diagnosis, and treatment of a wide spectrum of genetic conditions, clinicians will become deft with the necessary knowledge and skills to address genetic and genomic challenges in a clinical setting. Additionally, the program ensures the successful execution of the Emirati Genome Program, bringing precision medicine to the forefront of public health policy formulation and implementation across the UAE.

“We are delighted to collaborate with the Department of Health – Abu Dhabi to launch this transformative training program,” said Alireza Haghighi, MD, DPhil, FACMG, Founding Director of the International Center for Genetic Disease. “As one of the largest and most comprehensive genomics educational programs worldwide, the primary goal is to enhance the knowledge and expertise of Emirati physicians. This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide. Our comprehensive partnership with the Department of Health – Abu Dhabi not only aims to advance life sciences but also to improve the well-being of the UAE population.”

Delivered by globally recognized Harvard-affiliated experts within the Mass General Brigham system and elsewhere, the program will enhance the knowledge and expertise of Emirati physicians, who will then be able to further incorporate the latest innovations in genomic medicine and genetic counseling into the clinical care of patients. The iCGD designed the program to specifically address the public health needs of the UAE.

“We are dedicated to enhancing patient care, preventing disease, and promoting the widespread adoption of genomic medicine, both locally and globally,” said Robert S.D. Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham. “Our International Center for Genetic Disease provides an ideal platform to realize these objectives. This transformative training program aims to cultivate a professional workforce in the UAE at the forefront of genomic research and clinical applications.”

The inaugural ceremony, held in Abu Dhabi, UAE, on October 30th, was attended by prominent Emirati officials, including His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi; Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi; Professor Sir John O’Reilly, President of Khalifa University; and His Excellency Homaid Al Shimmari, Vice Chairman of the Board of Trustees of Khalifa University.

“This program comes as a continuation of our collaboration with the International Center for Genetic Disease (iCGD) and Harvard Medical School which started earlier this year, providing the world with genomic solutions that address international health challenges and needs,” said Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi. “This comes in line with the Department of Health’s efforts to unlock opportunities for local talents and ensure the sustainability of our healthcare sector. These continuous strides further cement Abu Dhabi’s position as a leading destination for healthcare.”

“We are delighted to join with our partners to launch the Clinical Genomics and Genetic Counseling course in the realm of healthcare at Khalifa University,” said Professor Sir John O’Reilly, President of Khalifa University. “Developments in this area represent a tremendous leap towards empowering individuals with a profound understanding of their own genetic tapestry.”

Advances in genomics, clinical diagnostic methods and therapies are now fueling healthcare. By integrating clinical data and genetic information, healthcare providers can improve population screening, diagnosis, prognosis, risk management, and in some cases, offer new and innovative targeted therapy for conditions such as cardiovascular diseases, hemoglobinopathies, lipid disorders, diabetes, cancer, among many other clinically complex morbidities.

About the International Center for Genetic Disease (iCGD)
The International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital and Harvard Medical School is dedicated to enhancing genomic medicine worldwide, focusing on the analysis of populations from various parts of the world for genetic research into human health and disease, with the ultimate goal of improving public health. iCGD serves as a nexus, bringing together unparalleled knowledge and expertise, as well as unmatched dedication to multidisciplinary research, cutting-edge technology, and innovative methods to bridge gaps in knowledge and practice in the realm of genomic medicine. iCGD forms partnerships with government, academic institutions, and industry, focusing on translational and clinical research, capacity building, and technology transfer, with the aim of enhancing access to genomic medicine for everyone, not just the affluent or the fortunate. For more information, please visit https://icgd.bwh.harvard.edu/

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

Noah Brown
Mass General Brigham
Nbrown9@mgb.org

GlobeNewswire Distribution ID 8982687

International Center for Genetic Disease, Mass General Brigham launches a global Clinical Genomic Medicine and Genetic Counseling training program in United Arab Emirates

Collaboration between the International Center for Genetic Disease and the Department of Health – Abu Dhabi, advances state-of-the-art precision medicine approaches and techniques, tailoring prevention, diagnosis, and treatment of diseases for the Emirati population. This collaboration encompasses three strategic pillars: clinical and translational research, capacity building and technology transfer, and commercialization.

Boston, MA, Nov. 20, 2023 (GLOBE NEWSWIRE) — Genomic medicine, also known as precision medicine, offers transformative opportunities to reshape health care and public health from a ‘one size fits all’ approach to one utilizing an individual’s genetic profile, informing their personalized care pathway from prevention and diagnosis, to treatment of diseases and the development of novel and more effective drugs. To help further genomic medicine’s global promise, the International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital (a founding member of the Mass General Brigham system) and Harvard Medical School, is launching a six-month nationwide program to train 100 physicians across the United Arab Emirates (UAE) in clinical genomic medicine and genetic counseling. This training program is implemented in collaboration with the Department of Health – Abu Dhabi and Khalifa University of Science and Technology. The comprehensive partnership between iCGD, Mass General Brigham, and the Department of Health – Abu Dhabi will help advance life sciences and health care outcomes across the globe while leveraging the advanced genomics capabilities of the Emirate.

With an emphasis on screening, diagnosis, and treatment of a wide spectrum of genetic conditions, clinicians will become deft with the necessary knowledge and skills to address genetic and genomic challenges in a clinical setting. Additionally, the program ensures the successful execution of the Emirati Genome Program, bringing precision medicine to the forefront of public health policy formulation and implementation across the UAE.

“We are delighted to collaborate with the Department of Health – Abu Dhabi to launch this transformative training program,” said Alireza Haghighi, MD, DPhil, FACMG, Founding Director of the International Center for Genetic Disease. “As one of the largest and most comprehensive genomics educational programs worldwide, the primary goal is to enhance the knowledge and expertise of Emirati physicians. This initiative is designed to integrate genetics and genomics into patient care effectively, underscoring our dedication to enhancing genomic medicine worldwide. Our comprehensive partnership with the Department of Health – Abu Dhabi not only aims to advance life sciences but also to improve the well-being of the UAE population.”

Delivered by globally recognized Harvard-affiliated experts within the Mass General Brigham system and elsewhere, the program will enhance the knowledge and expertise of Emirati physicians, who will then be able to further incorporate the latest innovations in genomic medicine and genetic counseling into the clinical care of patients. The iCGD designed the program to specifically address the public health needs of the UAE.

“We are dedicated to enhancing patient care, preventing disease, and promoting the widespread adoption of genomic medicine, both locally and globally,” said Robert S.D. Higgins, MD, MSHA, President of Brigham and Women’s Hospital and Executive Vice President at Mass General Brigham. “Our International Center for Genetic Disease provides an ideal platform to realize these objectives. This transformative training program aims to cultivate a professional workforce in the UAE at the forefront of genomic research and clinical applications.”

The inaugural ceremony, held in Abu Dhabi, UAE, on October 30th, was attended by prominent Emirati officials, including His Excellency Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi; Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi; Professor Sir John O’Reilly, President of Khalifa University; and His Excellency Homaid Al Shimmari, Vice Chairman of the Board of Trustees of Khalifa University.

“This program comes as a continuation of our collaboration with the International Center for Genetic Disease (iCGD) and Harvard Medical School which started earlier this year, providing the world with genomic solutions that address international health challenges and needs,” said Her Excellency Dr. Noura Al Ghaithi, Undersecretary at the Department of Health – Abu Dhabi. “This comes in line with the Department of Health’s efforts to unlock opportunities for local talents and ensure the sustainability of our healthcare sector. These continuous strides further cement Abu Dhabi’s position as a leading destination for healthcare.”

“We are delighted to join with our partners to launch the Clinical Genomics and Genetic Counseling course in the realm of healthcare at Khalifa University,” said Professor Sir John O’Reilly, President of Khalifa University. “Developments in this area represent a tremendous leap towards empowering individuals with a profound understanding of their own genetic tapestry.”

Advances in genomics, clinical diagnostic methods and therapies are now fueling healthcare. By integrating clinical data and genetic information, healthcare providers can improve population screening, diagnosis, prognosis, risk management, and in some cases, offer new and innovative targeted therapy for conditions such as cardiovascular diseases, hemoglobinopathies, lipid disorders, diabetes, cancer, among many other clinically complex morbidities.

About the International Center for Genetic Disease (iCGD)
The International Center for Genetic Disease (iCGD) at Brigham and Women’s Hospital and Harvard Medical School is dedicated to enhancing genomic medicine worldwide, focusing on the analysis of populations from various parts of the world for genetic research into human health and disease, with the ultimate goal of improving public health. iCGD serves as a nexus, bringing together unparalleled knowledge and expertise, as well as unmatched dedication to multidisciplinary research, cutting-edge technology, and innovative methods to bridge gaps in knowledge and practice in the realm of genomic medicine. iCGD forms partnerships with government, academic institutions, and industry, focusing on translational and clinical research, capacity building, and technology transfer, with the aim of enhancing access to genomic medicine for everyone, not just the affluent or the fortunate. For more information, please visit https://icgd.bwh.harvard.edu/

About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.

Noah Brown
Mass General Brigham
Nbrown9@mgb.org

GlobeNewswire Distribution ID 8982687

RSPO Celebrates 20 Years of Impact and Reaffirms the Power of Partnerships for the Next 20

Collective action and innovative practices sowed within the industry are reaping results, with RSPO global certification, membership, production and consumption volumes steadily on the rise, alongside greater environmental stewardship

Opening Speech

RSPO Chief Executive Officer delivering the opening speech at RSPO RT2023

JAKARTA, Indonesia, Nov. 21, 2023 (GLOBE NEWSWIRE) — The Roundtable on Sustainable Palm Oil marked a special milestone at its Annual Roundtable conference (RT2023), themed “Partners for the Next 20”, to reflect on nearly two decades of impact made possible through the collaborative efforts of RSPO’s Members and partners. RT2023 presented an opportunity to take unified action on the core challenges facing the sustainable palm oil industry, including mitigating climate change, increasing uptake of certified sustainable palm oil (CSPO), protecting labour rights, and facilitating greater smallholder inclusion in green supply chains through compliance with emerging international regulations.

For nearly twenty years, the RSPO has facilitated global change to make the production and consumption of palm oil sustainable. Starting from 200 members from 16 countries in 2004, RSPO now counts more than 5,700 members in over 100 countries and territories spanning the globe.

In his opening remarks, RSPO CEO Joseph D’Cruz said, “Through nearly two decades of voluntary action, RSPO Members have banded together to raise the bars of sustainability within the industry. The impact we have collectively achieved is increasingly being acknowledged by stakeholders outside our industry, and we are seeing a definite shift in the sustainable palm oil narrative in our favour. As a global partnership to make palm oil sustainable, we must ride this trajectory and continue to evolve and pursue new territory. There is room now for us to move beyond a standard and certification system and develop tools that would enable the industry to demonstrate sustainability in the way that markets, regulators and customers demand today.”

Opening Speech

RSPO Chief Executive Officer delivering the opening speech at RSPO RT2023

RSPO’s key achievements over the last two decades were highlighted, including the increase in global certified area from just 125,000 hectares in 2008 to 4.9 million hectares across 23 countries in 2023. Certified Sustainable Palm Oil (CSPO) supply reached a new milestone at 15.4 million metric tonnes, while RSPO Trademark licences have increased significantly to more than 1,600 licences in over 100 countries and territories, with growth seen in China, Japan and Southeast Asia, signalling significant opportunities in these markets. The RSPO Smallholder Support Fund (RSSF) has provided US$4.2 million in funding to support 44,203 farmers in 12 countries since 2013. Accounting for 40% of total palm oil production output in key producing countries, smallholders featured strongly at RT2023, focused on opportunities and pathways to facilitate greater inclusion in green supply chains through compliance with emerging international regulations.

Independent Smallholders

Group photo of Independent Smallholders with their certificates

Charting new territory, RSPO’s Certification, Trade and Traceability System (CTTS), launched recently in October 2023 with the formation of the tripartite consortium of global agri-tech experts, exemplifies how the organisation is advancing and digitising its tracking and traceability systems into an end-to-end digital infrastructure. This is rooted by best-in-class solutions that will be able to meet current demands and anticipate the future needs of a sector that is rapidly evolving to meet tightening global regulations, starting with the EU Deforestation Regulation (EUDR), and is actively engaging with the European Commission for knowledge-sharing on this topic with all relevant parties.

Excellence Awards

Winners of the Excellence Awards from left to right: DSN Group, Bumitama Agri Ltd, Musim Mas, Cheyenne Mountain Zoo, WWF International

Anne Rosenbarger and José Roberto Montenegro, Co-Chairs of the RSPO Board of Governors, together called for the successes of the past 20 years to be leveraged and scaled further through collective action and innovative approaches. “RSPO is strategically evolving to meet current and forthcoming challenges, including shifting regulatory and market expectations, by improving the auditability and implementability of our current standards and Assurance systems in order to be ready to connect to the broader industry’s sustainability platforms,” said Anne Rosenbarger. Following a comprehensive and highly consultative review of its current 2018 RSPO Principles and Criteria and 2019 RSPO Independent Smallholder Standard, a technical revision process is underway to produce a revised set of standards in 2024.

Opening performance

Opening performance at the RSPO RT2023 opening ceremony

The conference also featured the RSPO Excellence Awards, which saw fifteen of its Members nominated for their outstanding contributions to sustainable palm oil. The winners were DSN Group for Innovation; Bumitama Agri Ltd. for Conservation Leadership; Musim Mas for Smallholder Impact; Cheyenne Mountain Zoo for Communicating for Good, and WWF International for Shared Responsibility. Learn more about the winners, nominees and their award-worthy initiatives here.

About RSPO:
The Roundtable on Sustainable Palm Oil (RSPO) is a global partnership to make palm oil sustainable. Formed in 2004, the RSPO is a multi-stakeholder non-profit organisation that unites members from across the palm oil value chain, including oil palm producers, palm oil processors and traders, consumer goods manufacturers, retailers, banks, and investors, environmental or nature conservation non-governmental organisations (NGOs), and social or developmental NGOs. As a partnership for progress and positive impact, the RSPO facilitates global change to make the production and consumption of palm oil sustainable. To inspire change, we communicate the environmental and social benefits. To make progress, we catalyse collaboration. To provide assurance, we set the standards of certification. The RSPO is registered as an international association in Zurich, Switzerland, with main offices in Malaysia and Indonesia, and offices in China, Colombia, Netherlands, United Kingdom, and the United States. For further information, kindly contact: media@rspo.org

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/e3d1362b-d6ca-411e-a334-d3329fe61b08

https://www.globenewswire.com/NewsRoom/AttachmentNg/ebf44138-e654-4d83-ac61-db282390dfeb

https://www.globenewswire.com/NewsRoom/AttachmentNg/87cbb14b-c9bb-4b10-baf6-c739f4aa65c9

https://www.globenewswire.com/NewsRoom/AttachmentNg/446698dc-9eba-45e4-bd33-f86e018dbf2d

https://www.globenewswire.com/NewsRoom/AttachmentNg/1a672127-c463-47b1-a951-7e93198cc3c9

For further information, kindly contact:

Kimasha Williams
Communications Manager Europe
kimasha.williams@rspo.org

Stephanie Ambrose
Communications Manager APAC
stephanie.ambrose@rspo.org

GlobeNewswire Distribution ID 8983091

‫XOOX، أول خدمة تواصل شبكي للحيوانات الأليفة (PNS) تلفت الأنظار لدى تدشينها

– تشتهر الخدمة بتحديات المحتوى المختصر وموسيقى الحيوانات الأليفة وتطبيق مجموعة تشخيص الأمراض، وغيرها.

– توفير خدمة جديدة مع تسجيل مُعرف الهوية باستخدام أعين الحيوانات الأليفة

نيويورك، 21 نوفمبر 2023 (GLOBE NEWSWIRE) — يشتمل تطبيق خدمة التواصل الشبكي للحيوانات الأليفة، XOOX، على تحديات المحتوى المختصر، وقد تم تدشين التطبيق هذا الشهر واستقطب ملاك الحيوانات الأليفة على مستوى العالم. بدأ تطبيق XOOX تقديم خدماته من خلال إعلان في ميدان نيويورك تايمز، يؤكد على تركيزه الحصري على أصدقائنا من الحيوانات الأليفة ذات الأربعة أرجل.

يعمل تطبيق XOOX بشكل فريد بموجب حسابات حيوانات أليفة من خلال عملية تسجيل معرفات الحيوانات الأليفة التي ابتكرتها فرق الأبحاث والذكاء الاصطناعي العالمية لدى XOOX، بما في ذلك الخبراء البيطريين على مستوى العالم، باستخدام أساليب بيومترية للتعرف على الهوية، مثل أنماط الجفون وتجعدات العيون. وبهذه المناسبة، قال فريق أبحاث XOOX “من خلال مُعرف هوية الحيوانات الأليفة، يتم التعرف على الحيوانات الأليفة باعتبارها مستخدمة للحسابات على XOOX، مما يسمح لها بالانخراط في العديد من الأنشطة، مثل تسجيل الحيوانات الأليفة والتأمين وإدارة الصحة وتكوين الصداقات”، وأضاف “ومن أجل تعزيز دقة التسجيل البيومتري، قمنا باعتماد طريقة متقدمة بخطوة على طباعة الأنف والمسح الضوئي للحدقية”.

ومن خلال تطبيق XOOX، تصبح الحيوانات الأليفة مؤثرة من خلال معرفات الهوية الخاصة بكل منها، مما يعزز المعرفة بها عبر مشاركة حياتها اليومية واستقطاب المتابعين والمشاركة في تحديات المحتوى المختصر. وهي تكسب نقاطًا من خلال مختلف الأنشطة، قابلة للاستخدام في التطبيقات المتصلة، من أجل إنشاء الأفاتار ومشتريات المنتجات. يعمل ملاك الحيوانات الأليفة، والمعروفون كذلك باسم البتلر، على إدارة معرفات هوية حيواناتهم الأليفة ودعمها في أنشطتها. يرحب تطبيق XOOX بالأفراد الذين لا يملكون حيوانات أليفة ويشجعهم على الانضمام كذلك، مما يعمل على تعزيز التحول الإيجابي تجاه الحيوانات الأليفة. غير أن نشر المحتوى ليس خاصية متاحة لهم في هذا الوقت. وفي معرض تعليقه على هذه المناسبة، قال Peter Kim المستشار الفني في XOOX “يهدف تطبيق XOOX إلى إيجاد مساحة إيجابية حيث يستطيع الأشخاص المعاصرون الهروب من الواقع المعقد والتواصل مع حيواناتهم الأليفة”. وأضاف Kim “سوف يسمح XOOX للحيوانات الأليفة بإيجاد المزيد من الذكريات مع ملاك الحيوانات الأليفة عبر استخدام مناهج السرد والخدمات الفريدة والتعريفية”.

يشتمل عالم XOOX على الكثير من المحتوى الحصري للحيوانات الأليفة. ويتيح تطبيق الموسيقى الأكثر شعبية (XOOX M) لملاك الحيوانات الأليفة اختيار الموسيقى المناسبة لتفضيلات الحيوانات الأليفة. وقد تم تصميم هذا التطبيق، الذي تم قامت على تطويره شركة تطوير المحتوى الموسيقي التابعة لـXOOX وهي Jo studios (ورئيسها التنفيذي: Woojin Cho)، للحيوانات الأليفة التي تنتظر ملاكها ويستضيف حاليًا أكثر من 3,000 أغنية. يمكن لملاك الحيوانات الأليفة كذلك إنشاء محتوى الموسيقى الخاص بهم وتحميله وكسب النقاط مقابل الشهرة، ويمكنهم إنفاق تلك النقاط على حيواناتهم الأليفة. يضمن XOOX M تجربة استماع صديقة للحيوانات الأليفة مع مستوى ديسيبل مريح.

وبالإضافة إلى ذلك، يجري حاليًا العمل على تطوير منتج بواسطة شركة Push Pull System (ورئيسها التنفيذي: Sungmyon Song). ومن خلال تحليل أساليب التعلم العميق والاستفادة منها، فإن ذلك سيحدد ما إذا كانت الحيوانات الأليفة تستمتع حقًا بالموسيقى ولا تعتبرها ضوضاءً. سوف ينسجم المنتج بشكل سلس مع كاميرات وميكرفونات الحيوانات الأليفة، مما يوفر توصيات موسيقية مخصصة لحيواناتك الأليفة.

وبصفتك مالك حيوانات أليفة، يستحق الأمر أن تبدي الاهتمام بالحملة الحالية للترويج للتطبيق. وفي سبيل الاحتفاء بالتدشين، توزع XOOX نحو 10,000 مجموعة اختبار بول مجانية على مالكي الحسابات على مستوى العالم. توفر مجموعات الاختبار هذه طريقة سهلة لاكتشاف الأمراض من خلال بول الحيوانات، مما يجعلها مثالية للحيوانات الأليفة في المناطق ذات إمكانية الوصول المحدودة للرعاية البيطرية، مما يساعد في الحفاظ على رفاهية حيواناتك الأليفة المحبوبة.

وعلاوة على ذلك، واستنادًا إلى تدشين تطبيق مجموعات تشخيص أمراض الحيوانات الأليفة عن طريق البول باستخدام Medi Cloud، وهي شركة تحليلات جينية عالمية تعتمد على تقنية NGS، سوف تدشن XOOX كذلك تطبيقات تربط بين الحمض النووي للحيوانات الأليفة DNA واختبار تحليل الشخصية MBTI.

يتم التبرع بسنت واحد تلقائيًا إلى مؤسسة XOOX لدى التسجيل. وسوف يتم توجيه هذه المساهمات إلى الحملات على مستوى العالم التي تهدف إلى التأثير إيجابيًا على التشريعات المرتبطة بالحيوانات الأليفة. ومن خلال قيام XOOX بتمكين الحيوانات الأليفة للنهوض بدور محوري في عالمنا، ثمة إيمان قوي بأنه سيسهم بقوة في إيجاد بيئة أكثر دعمًا وملاءمة للحيوانات الأليفة.

مسؤول جهة الاتصال:

XOOX LAB, INC

www.xoox.pet

Kristen Kim

الهاتف: ‎+1 (213) 944-2679

البريد الإلكتروني: press@xoox.pet

تتوفر صورة فوتوغرافية مصاحبة لهذا الإعلان على https://prdesk.globenewswire.com/api/ResourceLibraryFile/DownloadFile?source=pnr&Id=1f092720-eaa2-478b-8bd4-99fa5c3fc51c

GlobeNewswire Distribution ID 3693331